
    
      The effect of Carvedilol CR on Micro T-Wave Alternans will be assessed in 30 hypertensives
      with stage 4 or 5 chronic kidney disease utilizing a cross-over design and contrasting no
      treatment against active treatment periods of 8 weeks.
    
  